241 related articles for article (PubMed ID: 25926554)
1. Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic.
Sarkar S; Quinn BA; Shen XN; Dash R; Das SK; Emdad L; Klibanov AL; Wang XY; Pellecchia M; Sarkar D; Fisher PB
Oncotarget; 2015 May; 6(13):10712-27. PubMed ID: 25926554
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention gene therapy (CGT) of pancreatic cancer using perillyl alcohol and a novel chimeric serotype cancer terminator virus.
Sarkar S; Azab B; Quinn BA; Shen X; Dent P; Klibanov AL; Emdad L; Das SK; Sarkar D; Fisher PB
Curr Mol Med; 2014 Jan; 14(1):125-40. PubMed ID: 24236457
[TBL] [Abstract][Full Text] [Related]
3. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus.
Sarkar D; Lebedeva IV; Su ZZ; Park ES; Chatman L; Vozhilla N; Dent P; Curiel DT; Fisher PB
Cancer Res; 2007 Jun; 67(11):5434-42. PubMed ID: 17545625
[TBL] [Abstract][Full Text] [Related]
4. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.
Dash R; Azab B; Quinn BA; Shen X; Wang XY; Das SK; Rahmani M; Wei J; Hedvat M; Dent P; Dmitriev IP; Curiel DT; Grant S; Wu B; Stebbins JL; Pellecchia M; Reed JC; Sarkar D; Fisher PB
Proc Natl Acad Sci U S A; 2011 May; 108(21):8785-90. PubMed ID: 21555592
[TBL] [Abstract][Full Text] [Related]
5. Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV).
Azab BM; Dash R; Das SK; Bhutia SK; Sarkar S; Shen XN; Quinn BA; Dent P; Dmitriev IP; Wang XY; Curiel DT; Pellecchia M; Reed JC; Sarkar D; Fisher PB
J Cell Physiol; 2014 Jan; 229(1):34-43. PubMed ID: 23868767
[TBL] [Abstract][Full Text] [Related]
6. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
[TBL] [Abstract][Full Text] [Related]
7. Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine.
Dash R; Richards JE; Su ZZ; Bhutia SK; Azab B; Rahmani M; Dasmahapatra G; Yacoub A; Dent P; Dmitriev IP; Curiel DT; Grant S; Pellecchia M; Reed JC; Sarkar D; Fisher PB
Cancer Res; 2010 Jun; 70(12):5034-45. PubMed ID: 20501829
[TBL] [Abstract][Full Text] [Related]
8. Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach.
Greco A; Di Benedetto A; Howard CM; Kelly S; Nande R; Dementieva Y; Miranda M; Brunetti A; Salvatore M; Claudio L; Sarkar D; Dent P; Curiel DT; Fisher PB; Claudio PP
Mol Ther; 2010 Feb; 18(2):295-306. PubMed ID: 19888195
[TBL] [Abstract][Full Text] [Related]
9. Unique conditionally replication competent bipartite adenoviruses-cancer terminator viruses (CTV): efficacious reagents for cancer gene therapy.
Sarkar D; Su ZZ; Fisher PB
Cell Cycle; 2006 Jul; 5(14):1531-6. PubMed ID: 16861924
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
Lian J; Ni Z; Dai X; Su C; Smith AR; Xu L; He F
Mol Cancer Ther; 2012 Feb; 11(2):416-26. PubMed ID: 22188816
[TBL] [Abstract][Full Text] [Related]
11. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
Jackson RS; Placzek W; Fernandez A; Ziaee S; Chu CY; Wei J; Stebbins J; Kitada S; Fritz G; Reed JC; Chung LW; Pellecchia M; Bhowmick NA
Neoplasia; 2012 Jul; 14(7):656-65. PubMed ID: 22904682
[TBL] [Abstract][Full Text] [Related]
12. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.
Azab B; Dash R; Das SK; Bhutia SK; Shen XN; Quinn BA; Sarkar S; Wang XY; Hedvat M; Dmitriev IP; Curiel DT; Grant S; Dent P; Reed JC; Pellecchia M; Sarkar D; Fisher PB
J Cell Physiol; 2012 May; 227(5):2145-53. PubMed ID: 21780116
[TBL] [Abstract][Full Text] [Related]
13. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
14. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
15. Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic.
Sarkar S; Pradhan A; Das SK; Emdad L; Sarkar D; Pellecchia M; Fisher PB
Oncoimmunology; 2016 Mar; 5(3):e1078059. PubMed ID: 27141334
[TBL] [Abstract]
